Friday, 19 Oct 2018

You are here

Patterns of Biologic Use During Autoimmune Pregnancy

While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.

This becomes problematic in autoimmune patients, many of whom are women of child bearing potential, who may have active disease that mandates the use of corticosteroids, immunosuppressives or biologics to maintain maternal health.

This issue was studied by Tsao et al who showed increased biologic utilization of biologics and high rates of discontinuation during pregnancy in women with autoimmune disease. 

A Canadian cohort of women with one or more autoimmune diseases was studied between January 1st, 2002 and December 31st, 2012; those with >1 biologic before, or during, pregnancy were included.

Among 6,218 women (8,431 pregnancies) with autoimmune diseases, they found 131 women (144 pregnancies) exposed to a biologic before or during pregnancy.  This included women with RA (51%), IBD 46%, JIA 8%, AS 6% and MS 5%. 

Biologic use increased over 12 years from 0% to 5.7% by 2012 (p<0.001). Within the first trimester of pregnancy, 31% (34/110) of women discontinued their biologic and 38% (30/79) discontinued in the second trimester, while 98% (50/51) of those who were on treatment in the second trimester remained on treatment in the third trimester.

Women with rheumatoid arthritis (RA) had three times greater odds (OR 3.40 [95%CI 1.33-8.71]) of discontinuing biologics during pregnancy, compared to those with inflammatory bowel disease.

These data suggest the need for more research regarding the use, risks and benefits of biologics on fetal and maternal health.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia. While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events. A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.